Celltrion unveils promising results for four-target obesity drug

Celltrion has unveiled promising preclinical results for its next-generation obesity drug candidate, CT-G32/SCO-940, which outperformed a leading experimental weight-loss treatment in animal testing and showed potential to better preserve lean body mass. The South Korean biopharmaceutical company presented the findi…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.